RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancerElena Élez, Rodrigo A. Toledo, Javier Gonzalo‐Ruiz et al.|Nature Medicine|2022Cited by 111
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor HypoxiaRodrigo A. Toledo, Patricia L. M. Dahia, Camilo Jiménez et al.|Endocrine Reviews|2022Cited by 86
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNAAriana Huebner, Rodrigo A. Toledo, James R. Black et al.|Genome Medicine|2023Cited by 8
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Charles W. Abbott et al.|Clinical Cancer Research|2025Cited by 1
Additional file 2 of ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNAAriana Huebner, Rodrigo A. Toledo, James R. Black et al.|Open MIND|2023Cited by 0